Literature DB >> 2053466

The human substantia nigra and ventral tegmental area. A neuroanatomical study with notes on aging and aging diseases.

P H van Domburg1, H J ten Donkelaar.   

Abstract

The present study comprises a cytoarchitectonic analysis of the human substantia nigra (SN) and ventral tegmental area (VTA); a discussion of their chemoarchitecture and fiber connections (mainly based on tract-tracing studies in primates) preceded by an overview of the wealth of tract-tracing data in rodents; a discussion of the involvement of the SN/VTA complex in Parkinson's disease (PD) and related disorders and in Alzheimer's disease (AD), including some quantitative data; and finally, some functional and pathophysiological considerations, relating nigral organization to pathophysiology and hypotheses on the etiology and distribution of AD and PD. DAergic cell populations in the mesencephalon (SN pars compacta, VTA, and the retrorubral area A8) which give rise to well-developed, DAergic, mesotelencephalic pathways, including a distinct mesostriatal system, and a substance P-immunoreactive striatotegmental system which projects to the SN pars reticulata and VTA appear to be common to reptiles, birds, and mammals (Sect. 3.1). The extensive literature on the organization of the SN/VTA complex in rats is summarized in Sect. 3.2. The mesotelencephalic projection is organized along inverted dorsal to ventral, medial to lateral, and rostral to caudal topographies. A dense DAergic innervation is characteristic of the entire striatal complex, including the caudate-putamen (the dorsal striatum), the nucleus accumbens, and the olfactory tubercle (the ventral striatum). This mesostriatal projection is compartmentally organized with distinct sets of DAergic neurons projecting to striosomes and extrasriosomal matrix, respectively, suggesting specialized channels directed at DAergic modulation of sensorimotor processing in the striatal matrix and limbic related mechanisms represented in the striosomal system. The VTA and medial part of the SN give rise to the DAergic mesolimbocortical system with extensive projections to limbic, allocortical, and neocortical structures. The striatonigral output pattern in rats is organized in such a way that the dorsal striatum mainly innervates the SN pars reticulata, whereas the ventral striatum projects predominantly to the VTA and medial part of the SN. Within the striatonigral projections in rats some interesting channels can be recognized, relating the sensorimotor cortex, via its corticostriatal projections, to that region of the SN giving rise to the nigrothalamic projection, and the visual cortex to the nigrotectal component of the SN pars reticulata.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2053466

Source DB:  PubMed          Journal:  Adv Anat Embryol Cell Biol        ISSN: 0301-5556            Impact factor:   1.231


  20 in total

1.  Pitx3-deficient aphakia mice display unique behavioral responses to psychostimulant and antipsychotic drugs.

Authors:  P A Ardayfio; A Leung; J Park; D-Y Hwang; T Moran-Gates; Y K Choi; W A Carlezon; F I Tarazi; K S Kim
Journal:  Neuroscience       Date:  2009-12-22       Impact factor: 3.590

2.  Activation of μ-opioid receptors in the dorsal striatum is necessary for adult social attachment in monogamous prairie voles.

Authors:  James P Burkett; Lauren L Spiegel; Kiyoshi Inoue; Anne Z Murphy; Larry J Young
Journal:  Neuropsychopharmacology       Date:  2011-07-06       Impact factor: 7.853

3.  Mapping dopaminergic deficiencies in the substantia nigra/ventral tegmental area in schizophrenia.

Authors:  Matthew W Rice; Rosalinda C Roberts; Miguel Melendez-Ferro; Emma Perez-Costas
Journal:  Brain Struct Funct       Date:  2014-10-01       Impact factor: 3.270

4.  Differential effects of intrastriatal 6-hydroxydopamine on cell number and morphology in midbrain dopaminergic subregions of the rat.

Authors:  Michelle Healy-Stoffel; S Omar Ahmad; John A Stanford; Beth Levant
Journal:  Brain Res       Date:  2014-06-09       Impact factor: 3.252

5.  Iron Oxide Nanoparticles Induce Dopaminergic Damage: In vitro Pathways and In Vivo Imaging Reveals Mechanism of Neuronal Damage.

Authors:  Syed Z Imam; Susan M Lantz-McPeak; Elvis Cuevas; Hector Rosas-Hernandez; Serguei Liachenko; Yongbin Zhang; Sumit Sarkar; Jaivijay Ramu; Bonnie L Robinson; Yvonne Jones; Bobby Gough; Merle G Paule; Syed F Ali; Zbigniew K Binienda
Journal:  Mol Neurobiol       Date:  2015-10       Impact factor: 5.590

6.  Amygdala pathology in Parkinson's disease.

Authors:  H Braak; E Braak; D Yilmazer; R A de Vos; E N Jansen; J Bohl; K Jellinger
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

7.  Three-dimensional and stereological characterization of the human substantia nigra during aging.

Authors:  Ana Tereza Di Lorenzo Alho; Claudia Kimie Suemoto; Lívia Polichiso; Edilaine Tampellini; Kátia Cristina de Oliveira; Mariana Molina; Glaucia Aparecida Bento Santos; Camila Nascimento; Renata Elaine Paraizo Leite; Renata Eloah de Lucena Ferreti-Rebustini; Alexandre Valotta da Silva; Ricardo Nitrini; Carlos Augusto Pasqualucci; Wilson Jacob-Filho; Helmut Heinsen; Lea Tenenholz Grinberg
Journal:  Brain Struct Funct       Date:  2015-09-19       Impact factor: 3.270

8.  Morphometry of the human substantia nigra in ageing and Parkinson's disease.

Authors:  Gay Rudow; Richard O'Brien; Alena V Savonenko; Susan M Resnick; Alan B Zonderman; Olga Pletnikova; Laura Marsh; Ted M Dawson; Barbara J Crain; Mark J West; Juan C Troncoso
Journal:  Acta Neuropathol       Date:  2008-02-23       Impact factor: 17.088

9.  Pitx3 deficiency produces decreased dopamine signaling and induces motor deficits in Pitx3(-/-) mice.

Authors:  Weidong Le; Lifen Zhang; Wenjie Xie; Song Li; John A Dani
Journal:  Neurobiol Aging       Date:  2015-08-20       Impact factor: 4.673

Review 10.  An update on the connections of the ventral mesencephalic dopaminergic complex.

Authors:  L Yetnikoff; H N Lavezzi; R A Reichard; D S Zahm
Journal:  Neuroscience       Date:  2014-04-13       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.